Quality, seriousness and credibility Only a press release can confirm our different assumptions on the chances of success of making it through the ultimate; obtaining different FDA designations, and ultimately, FDA approval and signing a jv deal with a big pharma and later on, being acquired by one.
But one thing is undeniable so far; the quality, seriousness and credibility:
- of the financial investment of management
Management has recently invested their own personal money in the company in May and participated in the latest pp
- of our R&D program (we're very close to something more than just the FDA Fast Track designation)
TLD1433 is now cited in many peer-review papers
- of our R&D partners:
... UHN,
...Princess Margaret Cancer Center (PMCC (#1 in Canada))
... Dr. Jewett
... Dr. Kulkarni
... prof. Lilge
... prof. McFarland
... Dr. Rueck
... prof. Vaugh-Betz
... IBM
... Intel,
... Special Pathogens Group, National Microbiology Laboratory (NML), Health Canada,
... Univ. of Manitoba,
... Dr. Coombs
... Dr. Kobasa
... Li Ka Shing Institute
... St-Michaels Hospital
... etc ...
- of our clinical data:
... NMIBC Ph. 1: DR of 67% (2 patients cancer free for 2y+ with a single dose)
... NMIBC Ph. 2: high CR% and promising high DR%
...COVID-19: promising preclinical data where TDL1433 kills SARS-2-COV within seconds, at tiny nanomolar doses. Spectacular enough to spark interest if NML in completing the last preclinical test.